Saudi Central Bank Increases Stake in Boston Scientific Corporation $BSX

Saudi Central Bank boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 8.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 642,847 shares of the medical equipment provider’s stock after buying an additional 49,313 shares during the period. Saudi Central Bank’s holdings in Boston Scientific were worth $28,164,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Boston Scientific during the second quarter worth $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific in the second quarter valued at $2,156,233,000. Norges Bank purchased a new position in Boston Scientific in the fourth quarter valued at $2,199,395,000. Jupiter Topco LLC acquired a new position in Boston Scientific during the 2nd quarter worth $803,357,000. Finally, Bank of America Corp DE purchased a new stake in Boston Scientific during the 2nd quarter worth about $556,026,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BSX shares. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Truist Financial lowered their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Bank of America reduced their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a report on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Stock Up 1.9%

Shares of NYSE BSX opened at $47.85 on Friday. The business has a 50-day moving average of $46.90 and a two-hundred day moving average of $55.74. The company has a market capitalization of $69.35 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the business posted $0.75 EPS. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.